Golden Eye (Propamidine Isetionate)

Golden Eye is indicated for the treatment and prevention of specific eye infections where a broad‑spectrum antiseptic is required.

• Acanthamoeba keratitis, particularly in contact‑lens wearers.
• Prophylaxis of postoperative ocular infections after cataract or refractive surgery.
• Management of contact‑lens‑related microbial keratitis caused by bacteria or fungi.
• Adjunctive therapy for bacterial conjunctivitis when conventional antibiotics are insufficient.
• Prevention of infection following corneal trauma or foreign‑body removal.
• Supportive care for mixed‑organism ocular infections in immunocompromised patients.

Adverse reactions to Golden Eye are generally mild, but serious events can occur, requiring medical attention. These effects are reported in clinical use and post‑marketing surveillance.

Common

• Transient stinging or burning sensation upon instillation.
• Mild ocular irritation or redness.
• Temporary blurred vision that resolves within minutes.
• Slight tearing or increased lacrimation.
• Mild eyelid swelling.

Serious

• Allergic contact keratitis presenting with persistent inflammation.
• Corneal epithelial defect or ulceration.
• Severe ocular pain or vision loss requiring urgent evaluation.
• Acute intraocular inflammation (uveitis).

When using Golden Eye, clinicians should consider several precautionary measures to minimize risk and ensure appropriate patient selection.

• Assess for known hypersensitivity to propamidine or related compounds before use.
• Use with caution in patients with pre‑existing corneal epithelial defects.
• Avoid prolonged use without ophthalmologic supervision.
• Do not apply to eyes with active viral infections such as herpes simplex keratitis.
• Monitor for signs of allergic reaction, especially in contact‑lens wearers.
• Pregnant or nursing patients should be evaluated individually, as safety data are limited.

Golden Eye may interact with other ophthalmic agents, and certain combinations should be avoided or used with caution.

Avoid

• Concurrent use with other topical antiseptics (e.g., povidone‑iodine) that may increase ocular irritation.
• Simultaneous administration of ophthalmic solutions containing preservatives that can potentiate toxicity.
• Mixing with ophthalmic anesthetics, which can exacerbate corneal toxicity.

Use with caution

• Co‑administration with topical corticosteroids, as steroids may mask early signs of irritation.
• Use alongside contact lens solutions containing disinfectants; rinse lenses thoroughly before re‑insertion.
• Combination with anti‑glaucoma eye drops; monitor intraocular pressure as irritation may affect measurements.
• Concurrent use with systemic antimicrobial therapy is generally safe but monitor for overlapping toxicity.